472 related articles for article (PubMed ID: 29593010)
21. The association between molecular type and prognosis of patients with stage IV breast cancer: an observational study based on SEER database.
Hou L; Qiu M; Chen M; Li F; Li J; Deng S; Yang Y; Du Z; Yang H
Gland Surg; 2021 Jun; 10(6):1889-1898. PubMed ID: 34268073
[TBL] [Abstract][Full Text] [Related]
22. Clinical features of patients with HER2-positive breast cancer and development of a nomogram for predicting survival.
Fan Y; Wang Y; He L; Imani S; Wen Q
ESMO Open; 2021 Aug; 6(4):100232. PubMed ID: 34392135
[TBL] [Abstract][Full Text] [Related]
23. Is the TNM staging system for breast cancer still relevant in the era of biomarkers and emerging personalized medicine for breast cancer - an institution's 10-year experience.
Orucevic A; Chen J; McLoughlin JM; Heidel RE; Panella T; Bell J
Breast J; 2015; 21(2):147-54. PubMed ID: 25600504
[TBL] [Abstract][Full Text] [Related]
24. Breast cancer in Ethiopia: evidence for geographic difference in the distribution of molecular subtypes in Africa.
Hadgu E; Seifu D; Tigneh W; Bokretsion Y; Bekele A; Abebe M; Sollie T; Merajver SD; Karlsson C; Karlsson MG
BMC Womens Health; 2018 Feb; 18(1):40. PubMed ID: 29444670
[TBL] [Abstract][Full Text] [Related]
25. Prognostic significance of tumor subtypes in male breast cancer: a population-based study.
Leone JP; Leone J; Zwenger AO; Iturbe J; Vallejo CT; Leone BA
Breast Cancer Res Treat; 2015 Aug; 152(3):601-9. PubMed ID: 26126972
[TBL] [Abstract][Full Text] [Related]
26. Breast Cancer Subtype as a Predictor of Lymph Node Metastasis according to the SEER Registry.
Mattes MD; Bhatia JK; Metzger D; Ashamalla H; Katsoulakis E
J Breast Cancer; 2015 Jun; 18(2):143-8. PubMed ID: 26155290
[TBL] [Abstract][Full Text] [Related]
27. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
[TBL] [Abstract][Full Text] [Related]
28. HR+/Her2- breast cancer in pre-menopausal women: The impact of younger age on clinical characteristics at diagnosis, disease management and survival.
De Camargo Cancela M; Comber H; Sharp L
Cancer Epidemiol; 2016 Dec; 45():162-168. PubMed ID: 27846443
[TBL] [Abstract][Full Text] [Related]
29. The impact of different tumour subtypes on management and survival of New Zealand women with Stage I-III breast cancer.
Lawrenson R; Lao C; Campbell I; Harvey V; Seneviratne S; Elwood M; Sarfati D; Kuper-Hommel M
N Z Med J; 2018 May; 131(1475):51-60. PubMed ID: 29771902
[TBL] [Abstract][Full Text] [Related]
30. Breast cancer survival by molecular subtype: a population-based analysis of cancer registry data.
Fallahpour S; Navaneelan T; De P; Borgo A
CMAJ Open; 2017 Sep; 5(3):E734-E739. PubMed ID: 28951445
[TBL] [Abstract][Full Text] [Related]
31. Screening status, tumour subtype, and breast cancer survival: a national population-based analysis.
O'Brien KM; Mooney T; Fitzpatrick P; Sharp L
Breast Cancer Res Treat; 2018 Nov; 172(1):133-142. PubMed ID: 30006795
[TBL] [Abstract][Full Text] [Related]
32. Prognostic Significance of Progesterone Receptor Expression in Estrogen-Receptor Positive, HER2-Negative, Node-Negative Invasive Breast Cancer With a Low Ki-67 Labeling Index.
Ono M; Tsuda H; Yoshida M; Shimizu C; Kinoshita T; Tamura K
Clin Breast Cancer; 2017 Feb; 17(1):41-47. PubMed ID: 27477822
[TBL] [Abstract][Full Text] [Related]
33. Parity, hormones and breast cancer subtypes - results from a large nested case-control study in a national screening program.
Ellingjord-Dale M; Vos L; Tretli S; Hofvind S; Dos-Santos-Silva I; Ursin G
Breast Cancer Res; 2017 Jan; 19(1):10. PubMed ID: 28114999
[TBL] [Abstract][Full Text] [Related]
34. Molecular subtypes predict the prognosis of male breast cancer: a retrospective cohort study.
Wang M; Liu D; Zhang Z; Dai X; Chen G; Zhu L
Transl Breast Cancer Res; 2023; 4():4. PubMed ID: 38751485
[TBL] [Abstract][Full Text] [Related]
35. Prognostic factors and survival according to tumour subtype in women presenting with breast cancer brain metastases at initial diagnosis.
Leone JP; Leone J; Zwenger AO; Iturbe J; Leone BA; Vallejo CT
Eur J Cancer; 2017 Mar; 74():17-25. PubMed ID: 28335884
[TBL] [Abstract][Full Text] [Related]
36. Heterogeneity of epidemiological factors by breast tumor subtypes in Korean women: a case-case study.
Song N; Choi JY; Sung H; Chung S; Song M; Park SK; Han W; Lee JW; Kim MK; Yoo KY; Ahn SH; Noh DY; Kang D
Int J Cancer; 2014 Aug; 135(3):669-81. PubMed ID: 24916400
[TBL] [Abstract][Full Text] [Related]
37. A retrospective prognostic evaluation analysis using the 8th edition of the American Joint Committee on Cancer staging system for breast cancer.
Lee SB; Sohn G; Kim J; Chung IY; Lee JW; Kim HJ; Ko BS; Son BH; Ahn SH
Breast Cancer Res Treat; 2018 Jun; 169(2):257-266. PubMed ID: 29388016
[TBL] [Abstract][Full Text] [Related]
38. Bcl-2 is a highly significant prognostic marker of hormone-receptor-positive, human epidermal growth factor receptor-2-negative breast cancer.
Seong MK; Lee JY; Byeon J; Sohn YJ; Seol H; Lee JK; Kim EK; Kim HA; Noh WC
Breast Cancer Res Treat; 2015 Feb; 150(1):141-8. PubMed ID: 25682076
[TBL] [Abstract][Full Text] [Related]
39. Molecular subtypes of screen-detected breast cancer.
Farshid G; Walters D
Breast Cancer Res Treat; 2018 Nov; 172(1):191-199. PubMed ID: 30046938
[TBL] [Abstract][Full Text] [Related]
40. [Clinical features and prognosis of patients with first-episode liver metastasis of different molecular subtypes of breast cancer].
Wu SY; Tan Y; Guan YS
Zhonghua Gan Zang Bing Za Zhi; 2016 Jun; 24(6):422-8. PubMed ID: 27465945
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]